Medgenics Announces Results of 2014 Annual Meeting of Stockholders
09 April 2014 - 10:30PM
Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG),
the developer of Biopump(TM) a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
ex-vivo gene therapy and their own tissue for the treatment of rare
and orphan diseases, today announced that all resolutions proposed
at the Company's Annual Meeting of Stockholders held yesterday were
duly passed.
Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr.
Alastair Clemow, Mr. Michael F. Cola, Mr. Wilbur H. Gantz, Mr.
Joseph J. Grano, Jr., Mr. Joel S. Kanter and Dr. Stephen D.
McMurray were reelected to the Board of Directors. Dr. Andrew L.
Pearlman retired from the Board of Directors at the meeting
following the expiration of his term. "On behalf of the Board of
Directors and the entire staff at Medgenics, I extend our deepest
gratitude to Andy Pearlman for his over a decade of service to the
company," said Sol J. Barer, Chairman of the Board of
Medgenics.
Stockholders approved the cancellation of the Company's common
stock shares from trading on the London Stock Exchange's
Alternative Investment Market, or AIM. The last day of trading of
the Company's common stock on AIM is expected to be April 15,
2014.
Stockholders also approved an amendment to the Company's Stock
Incentive Plan, increasing the number of shares authorized to be
issued under the plan by 2,000,000 shares.
Finally, stockholders ratified the appointment of Kost Forer
Gabbay & Kasierer, a member of Ernst & Young Global, to
serve as the Company's independent registered public accounting
firm for the year ended December 31, 2014.
Final voting tallies are subject to certification by the
Company's inspector of elections and will be included in a Current
Report on Form 8-K to be filed with the U.S. Securities and
Exchange Commission within the next week.
About Medgenics
Medgenics is developing and commercializing Biopump™, a
proprietary platform for the sustained production and delivery of
therapeutic proteins using ex-vivo gene therapy and the patient's
own tissue for the treatment of orphan and rare diseases. For more
information, visit the Company's website at www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
CONTACT: Medgenics, Inc.
John Leaman
john.leaman@medgenics.com
Stern Investor Relations
Beth DelGiacco
212-362-1200
Beth@sternir.com
Abchurch Communications
Harriet Rae / Joanne Shears/Jamie Hooper
+44 207 398 7719
jamie.hooper@abchurch-group.com
Oriel Securities (NOMAD & Broker)
Jonathan Senior / Giles Balleny
+44 207 710 7617
Medgenics (LSE:MEDU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics (LSE:MEDU)
Historical Stock Chart
From Jul 2023 to Jul 2024